Advertisement
Skip to Content

Insmed Inc INSM Stock Quote

| Rating as of

NASDAQ: INSM

Last close prices updated as of Jan 26, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 21.46
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 20.99  –  21.95
  • Year Range 16.41  –  28.94
  • Market Cap 2.9073 Bil
  • Volume / Avg 670,682.0 /  1.4 Mil
  • Price / Sales 10.59
  • Price / Book 53.62
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis INSM

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics INSM

Company Profile INSM

Business Description

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Contact
700 US Highway 202/206
Bridgewater, NJ, 08807
Industry Biotechnology
Employees 613

FAQs for Insmed Inc Stock

No. INSM does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

INSM’s market cap is 2.91 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

INSM’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

INSM’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare INSM’s historical performance against its industry peers and the overall market.